NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SNIPR Biome

SNIPR Biome

Private
CopenhagenHealthcare & Life Scienceshttps://www.sniprbiome.com/

Last Round

Series B

Aug 7, 2025

Total Funding Raised

$124.87M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SNIPR Biome is a biotechnology company that develops CRISPR-based medicines designed to treat microbial diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

CRISPR gene therapyphage therapymicrobial gene therapyantimicrobial resistanceAMRprecision antibioticsmicrobiome modulationCRISPR therapeuticsgut microbiome therapymicrobiome editingdrug-resistant bacterialiving medicinesbacteriophage deliveryE. coli treatmentgene therapy platformclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SNIPR Biome Comps

Public and private peers based on sector, stage, and business model.

SNIPR Biome comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

SNIPR Biome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 7, 2025
DebtDec 9, 2024
GrantApr 22, 2024
GrantMay 27, 2021
Series AMar 11, 2019
Seed
Jul 1, 2017

SNIPR Biome Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 15, 2025

    Developing a phage cocktail to treat Pseudomonas infections.

  • Aug 7, 2025

    $39.2M raised in Series B funding.

SNIPR Biome Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SNIPR Biome Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SNIPR Biome's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range46
Year Founded2017
Last FundingAug 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.